A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
NCT ID: NCT05056727
Last Updated: 2026-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1112 participants
INTERVENTIONAL
2021-09-30
2024-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
NCT04727528
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
NCT05347693
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
NCT04997161
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
NCT06185660
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
NCT03532009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specifically, the study will include participants with hyperkalaemia (S-K \> 5.0 to ≤ 6.5 mmol/L by central laboratory) who are on adequate or limited RAASi therapy due to hyperkalaemia, and participants with normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L by central laboratory) who are on limited RAASi therapy due to high risk of hyperkalaemia. High risk of hyperkalaemia is defined as (1) participants with a previous medical history or record of hyperkalaemia within the prior 24 months who are on limited RAASi therapy despite indication in CKD; (2) participants in whom RAASi therapy is indicated in CKD but are on limited RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L; and (3) participants in whom RAASi therapy has been discontinued or reduced to suboptimal doses because of hyperkalaemia.
A participant is expected to be in the study for approximately 28 months, which includes up to 13 days for the screening period, 27 months for the intervention period, and 1 week for follow-up. The 27-month intervention period of the study consists of 3 phases, an initiation phase (up to 72 hours), a run-in phase (3 months/up to Day 90), and a maintenance phase (24 months/104 weeks).
The initial dose of SZC will be administered to participants during the initiation phase. No changes will be made to the ACEi or ARB therapy at this stage. As soon as possible after the participant is confirmed to be normokalaemic at the end of the initiation phase, the participant will enter the run-in phase. Participants will receive open-label SZC and either lisinopril or valsartan. The aim of the run-in phase is to increase ACEi or ARB therapy stepwise to their maximum doses. After a 3-month run-in period for RAASi dose optimization while on SZC, participants will be randomized to SZC or placebo and followed during the subsequent 24 months of maintenance phase for efficacy and safety assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sodium Zirconium Cyclosilicate (SZC)
SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
Sodium Zirconium Cyclosilicate (SZC)
Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.
During Initiation Phase:
* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.
* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.
During Run-in and Maintenance Phases:
\- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water.
Lisinopril
Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
Valsartan
Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
Irbesartan
Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.
The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Placebo
Placebo + Lisinopril/Valsartan
Placebo
Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.
During Maintenance Phase:
\- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.
Lisinopril
Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
Valsartan
Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
Irbesartan
Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.
The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Zirconium Cyclosilicate (SZC)
Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.
During Initiation Phase:
* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.
* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.
During Run-in and Maintenance Phases:
\- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water.
Placebo
Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.
During Maintenance Phase:
\- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.
Lisinopril
Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
Valsartan
Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
Irbesartan
Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.
The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be ≥ 18 years of age at the time of signing the informed consent.
* Must have eGFR ≥ 25 and ≤ 59 mL/min/1.73m2 as calculated by central laboratory (CKD-EPI formula) at screening (Visit 1)
* Must have UACR ≥ 200 and ≤ 5000 mg/g as calculated by central laboratory at screening (Visit 1). If the first sample does not fulfil eligibility criteria, a second sample can be obtained during the screening period; if so, the UACR measurement from the second sample must be within the eligibility range.
* Any of the following criteria, a or b, at screening (Visit 1):
1. Cohort A: Hyperkalaemia (S-K \> 5.0 to ≤ 6.5 mmol/L) as measured by the central laboratory, and on adequate\* or limited\*\* RAASi therapy due to hyperkalaemia.
2. Cohort B: Normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L) as measured by the central laboratory and on limited\*\* RAASi therapy due to high risk of hyperkalaemia. High risk of hyperkalaemia is defined as:
(i) Participants with a previous medical history or record of hyperkalaemia within the prior 24 months, who are on limited\*\* RAASi therapy despite indication in CKD.
(ii) Participants in whom RAASi therapy is indicated in CKD, who are on limited\*\* RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L.
(iii) Participants in whom RAASi therapy has been discontinued or reduced to suboptimal\* doses because of hyperkalaemia.
\*Adequate RAASi dose levels are defined in protocol; doses lower than these are considered as suboptimal.
\*\*Limited RAASi therapy is defined as no or suboptimal RAASi therapy according to dosing guidance provided in protocol.
* If on thiazide or loop diuretics, the dose must have been stable for 2 weeks prior to screening (Visit 1).
* If on RAASi therapy, the dose must have been stable for one month prior to screening (Visit 1) and remain stable during screening.
* If on an SGLT2i treatment (ie, dapagliflozin and canagliflozin), finerenone, or any other medications in these 2 classes that are approved for CKD, the dose must have been stable for 3 months prior to screening (Visit 1).
* Participants must be one-year postmenopausal, surgically sterile, or using one highly effective form of birth control (defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly). They should have been stable on their chosen method of birth control for a minimum of one month prior to screening (Visit 1) and willing to remain on the birth control until one month after the last dose of study intervention.
Exclusion Criteria
* Myocardial infarction, unstable angina, stroke, or transient ischaemic attack within 3 months prior to screening (Visit 1).
* Participants with a known history of systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg within 2 weeks prior to screening (Visit 1) are excluded. In addition, any participant with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg as measured at screening (Visit 1) and confirmed by repeated measurement is excluded. Participants may be rescreened once blood pressure is controlled.
* QTcF \> 550 msec at screening (Visit 1).
* History of QT prolongation associated with other medications that required discontinuation of that medication.
* Congenital long QT syndrome.
* Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation and heart rate controlled by medication are permitted.
* Lupus nephritis or anti-neutrophil cytoplasmic antibody-associated vasculitis.
* Change in renal function requiring hospitalisation or dialysis within 3 months prior to screening (Visit 1).
* History of renal transplant (or anticipated need for renal transplant during the study).
* Severe hepatic impairment, biliary cirrhosis, or cholestasis.
* History of hereditary or idiopathic angioedema.
* Any prior hypersensitivity to ACEi or ARB that in the investigator's judgment precludes use of lisinopril and valsartan/irbesartan. Prior hypersensitivity reactions to consider include, but are not limited to, development of angioedema, icterus, hepatitis, or neutropaenia or thrombocytopaenia requiring treatment modification.
* Known hypersensitivity or previous anaphylaxis to SZC or to components thereof.
* Any condition outside the CV and renal disease area such as, but not limited to, malignancy, with a life expectancy of less than 2 years based on investigator´s clinical judgment.
* Active malignancy requiring treatment at the time of screening (Visit 1), except for successfully treated basal cell or treated squamous cell carcinoma.
* S-K \> 6.5 or \< 3.5 mmol/L by local laboratory within 1 day prior to the scheduled first dose of SZC in the initiation phase.
* Evidence of COVID-19 infection within 2 weeks prior to screening (Visit 1).
* Treated with dual blockade of RAAS (combined use of an ACEi and ARB) within 3 months prior to screening (Visit 1).
* Treated with an angiotensin receptor neprilysin inhibitor (ARNI; sacubitril/valsartan \[Entresto®\]) within 3 months prior to screening (Visit 1).
* Treated with an MRA not approved for CKD within 3 months prior to screening (Visit 1).
* Treated with aliskiren-containing products with 3 months prior to screening (Visit 1).
* Treated with SPS (eg, Kayexalate, Resonium), CPS (Resonium Calcium), patiromer (Veltassa®), or SZC (Lokelma®) within 7 days prior to screening (Visit 1).
* Participation in another clinical study with an investigational product administered within one month prior to screening (Visit 1).
* Not willing or not able to change to lisinopril or valsartan/irbesartan, the protocol-mandated RAASi study intervention. Note: For participants taking a fixed combination of an ACEi or ARB with another agent (eg, calcium blockers or diuretics) as SoC, the investigator must make a judgment that it will be safe and efficacious for such participants to change to the study ACEi or ARB and to the other drug as separate agents.
* Previous dosing with SZC in the present study.
* Currently pregnant (confirmed with positive pregnancy test at screening \[Visit 1\]) or breastfeeding.
* Judgment by the investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenn M. Chertow, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Stanford University School of Medicine, Stanford, CA USA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Surprise, Arizona, United States
Research Site
Tucson, Arizona, United States
Research Site
Canyon Country, California, United States
Research Site
Chula Vista, California, United States
Research Site
Northridge, California, United States
Research Site
San Dimas, California, United States
Research Site
South Gate, California, United States
Research Site
Tarzana, California, United States
Research Site
Denver, Colorado, United States
Research Site
Boynton Beach, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Lauderdale Lakes, Florida, United States
Research Site
Ocoee, Florida, United States
Research Site
Temple Terrace, Florida, United States
Research Site
Nampa, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Oak Brook, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Louisville, Kentucky, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
Flint, Michigan, United States
Research Site
Saint Clair Shores, Michigan, United States
Research Site
Columbia, Missouri, United States
Research Site
Kansas City, Missouri, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Albany, New York, United States
Research Site
Great Neck, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Bethlehem, Pennsylvania, United States
Research Site
Chester, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Orangeburg, South Carolina, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Arlington, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Newport News, Virginia, United States
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
La Plata, , Argentina
Research Site
Mar del Plata, , Argentina
Research Site
Mar del Plata, , Argentina
Research Site
Rosario, , Argentina
Research Site
San Vicente, , Argentina
Research Site
Sarandí, , Argentina
Research Site
Curitiba, , Brazil
Research Site
Fortaleza, , Brazil
Research Site
Joinville, , Brazil
Research Site
Maringá, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Blagoevgrad, , Bulgaria
Research Site
Botevgrad, , Bulgaria
Research Site
Dupnitsa, , Bulgaria
Research Site
Gorna Oryahovitsa, , Bulgaria
Research Site
Gotse Delchev, , Bulgaria
Research Site
Kozloduy, , Bulgaria
Research Site
Lom, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Samokov, , Bulgaria
Research Site
Sandanski, , Bulgaria
Research Site
Silistra, , Bulgaria
Research Site
Sliven, , Bulgaria
Research Site
Smolyan, , Bulgaria
Research Site
Stara Zagora, , Bulgaria
Research Site
Yambol, , Bulgaria
Research Site
Saint John, New Brunswick, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Baotou, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guiyang, , China
Research Site
Hangzhou, , China
Research Site
Hefei, , China
Research Site
Hengyang, , China
Research Site
Huizhou, , China
Research Site
Lanzhou, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Ningbo, , China
Research Site
Sanya, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shantou, , China
Research Site
Shengyang, , China
Research Site
Shenyang, , China
Research Site
Shenzhen, , China
Research Site
Taiyuan, , China
Research Site
Ürümqi, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuxi, , China
Research Site
Xi'an, , China
Research Site
Xuzhou, , China
Research Site
Yantai, , China
Research Site
Yinchuan, , China
Research Site
Zhengzhou, , China
Research Site
Zhuzhou, , China
Research Site
Coimbatore, , India
Research Site
Kolkata, , India
Research Site
Madurai, , India
Research Site
New Delhi, , India
Research Site
Bari, , Italy
Research Site
Bassano del Grappa, , Italy
Research Site
Bologna, , Italy
Research Site
Brescia, , Italy
Research Site
Messina, , Italy
Research Site
Pavia, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Rozzano, , Italy
Research Site
San Giovanni Rotondo, , Italy
Research Site
Verona, , Italy
Research Site
Amagasaki-shi, , Japan
Research Site
Atsugi-shi, , Japan
Research Site
Chiba, , Japan
Research Site
Chuo-shi, , Japan
Research Site
Chūōku, , Japan
Research Site
Chūōku, , Japan
Research Site
Fukuoka, , Japan
Research Site
Kamakura-shi, , Japan
Research Site
Kanoya-shi, , Japan
Research Site
Kasugai-shi, , Japan
Research Site
Kawachinagano-shi, , Japan
Research Site
Kawasaki-shi, , Japan
Research Site
Kitakyushu, , Japan
Research Site
Kitakyushu-shi, , Japan
Research Site
Koriyama-shi, , Japan
Research Site
Koshigaya-shi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kure-shi, , Japan
Research Site
Marugame-shi, , Japan
Research Site
Matsumoto-shi, , Japan
Research Site
Matsusaka-shi, , Japan
Research Site
Matsuyama, , Japan
Research Site
Nagoya, , Japan
Research Site
Nagoya, , Japan
Research Site
Naka, , Japan
Research Site
Noda, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Ōmihachiman, , Japan
Research Site
Sakaishi, , Japan
Research Site
Takarazuka-shi, , Japan
Research Site
Toyota, , Japan
Research Site
Toyota-Shi, , Japan
Research Site
Tsu, , Japan
Research Site
Tsuchiura-shi, , Japan
Research Site
Urayasu-shi, , Japan
Research Site
Yaizu-shi, , Japan
Research Site
Yokohama, , Japan
Research Site
Yokohama, , Japan
Research Site
Yokohama, , Japan
Research Site
Yonago-shi, , Japan
Research Site
Alor Star, , Malaysia
Research Site
Batu Caves, , Malaysia
Research Site
Johor Bahru, , Malaysia
Research Site
Kajang, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Seri Manjung, , Malaysia
Research Site
Cuauhtémoc, , Mexico
Research Site
Culiacán, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
Mazatlán, , Mexico
Research Site
Mérida, , Mexico
Research Site
Mérida, , Mexico
Research Site
México, , Mexico
Research Site
México, , Mexico
Research Site
San Luis Potosí City, , Mexico
Research Site
Veracruz, , Mexico
Research Site
Davao City, , Philippines
Research Site
Iloilo City, , Philippines
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Poznan, , Poland
Research Site
Rzeszów, , Poland
Research Site
Tczew, , Poland
Research Site
Ponce, , Puerto Rico
Research Site
Aramil, , Russia
Research Site
Moscow, , Russia
Research Site
Perm, , Russia
Research Site
Rostov-on-Don, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Almería, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Getafe, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Lugo, , Spain
Research Site
Madrid, , Spain
Research Site
Santa Cruz de Tenerife, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Valencia, , Spain
Research Site
Hualien City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Keelung, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Chaingmai, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Ratchathewi, , Thailand
Research Site
Adapazarı, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Antalya, , Turkey (Türkiye)
Research Site
Gaziantep, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Kahramanmaraş, , Turkey (Türkiye)
Research Site
Kayseri, , Turkey (Türkiye)
Research Site
Kocaeli, , Turkey (Türkiye)
Research Site
Dnipropetrovsk, , Ukraine
Research Site
Kharkiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Lutsk, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Zaporizhzhia, , Ukraine
Research Site
Zhytomyr, , Ukraine
Research Site
Biên Hòa, , Vietnam
Research Site
Da Nang, , Vietnam
Research Site
Hanoi, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Huế, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-001911-96
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
D9488C00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.